Search API
The U.S. Department of State updated its Travel Advisory for the Republic of Peru regarding civil unrest.
On June 1, 2023, the State Department's Level 2: Exercise Increased Caution advisory confirmed visitors should not travel to:
- The Colombian-Peruvian border area in the Loreto Region.
- The Valley of the Apurímac, Ene, and Mantaro Rivers, including areas within the Departments of Ayacucho, Cusco, Huancavelica, and Junin.
- The Puno Region, including the Peruvian side of Lake Titicaca, and the Apurimac Region.
And the U.S. Embassy in Lima recently reported a 24-hour strike is expected to affect the Puno region on May 31, 2023. In addition, roadblocks could disrupt travel within the area and the city of Puno.
Furthermore, U.S. travelers participating in Ayahuasca and Kambo ceremonies should be aware that numerous persons, including U.S. citizens, have reported that while under the influence of these substances, they have witnessed or been victims of sexual assault, rape, theft, serious health problems and injuries, and even death.
Previously, Machu Picchu reopened to visitors in late February 2023 after a short closure.
If you visit Peru, the State Department suggests enrolling in the Smart Traveler Enrollment Program to receive alerts in an emergency.
From a health perspective, the U.S. CDC included Peru in its recent dengue outbreak advisory.
A new repository of drug-dependence technical reports and resources was launched by the World Health Organization (WHO) on June 1, 2023, empowering its audience to source information within a single webpage.
The repository from WHO’s Expert Committee on Drug Dependence (ECDD) is an essential resource for health professionals, drug policy experts, and policy-makers, as many of the substances reviewed by ECDD have otherwise limited information regarding their public health risk.
It represents the only online, freely accessible collection of information and reports on new psychoactive substances and medicines for medical and scientific use, comprising over 450 substances.
The U.S. Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Update CDCHAN-00492 to supplement the HAN issued on May 17, 2023, offering updates on the ongoing fungal meningitis outbreak.
As of June 1, 2023, a multistate outbreak of fungal meningitis is ongoing among patients who underwent procedures under epidural anesthesia in the city of Matamoros, Tamaulipas, Mexico, at two clinics: River Side Surgical Center and Clinica K-3.
A total of 212 residents in 25 U.S. states and jurisdictions have been identified who might be at risk of fungal meningitis because they received epidural anesthesia at the clinics of interest in 2023.
Three of these patients (two probable cases and one confirmed case) have died.
Various laboratories have detected fungal signals consistent with the Fusarium solani species complex from the cerebrospinal fluid (CSF) of patients receiving follow-up care in Mexico or the U.S.
In addition, elevated levels of beta-D-glucan, a biomarker of fungal infection, have been detected in the CSF of at least six patients. Efforts by public health officials are ongoing to find and notify additional patients who might be at risk.
Healthcare providers, public health officials, and the public should be aware that all patients, including those without symptoms, who underwent medical or surgical procedures under epidural anesthesia in Matamoros, Mexico, since January 1, 2023, should be evaluated for fungal meningitis as soon as possible.
As of June 2, 2023, the WHO advises against the application of any travel or trade restrictions on Mexico and the U.S. based on the current information available on this event.
Nykode Therapeutics ASA today announced that it had expanded the clinical collaboration and supply agreement with Roche to cover the evaluation of VB10.16, an off-the-shelf therapeutic cancer vaccine candidate in development for the treatment of human papillomavirus type 16 (HPV16)-positive cancers.
This collaboration, unveiled on June 1, 2023, is evaluating the combination with Roche’s cancer immunotherapy atezolizumab in patients with advanced cervical cancer who have progressed on pembrolizumab plus chemotherapy +/- bevacizumab as first-line treatment.
The VB-C-04 clinical trial is expected to be initiated in the U.S. in the fourth quarter of 2023 with registrational intent, which provides a potential fast-to-market path.
“We look forward to expanding our collaboration with Roche to bring the combination of VB10.16 and atezolizumab to cervical cancer patients with limited treatment options. Cervical cancer has a poor prognosis, and the recent positive clinical data from VB-C-02 has strengthened our commitment to contribute to a well-tolerated treatment that can potentially prolong the life of these women. The trial provides a potential fast path to market for VB10.16,” commented Michael Engsig, CEO of Nykode Therapeutics, in a press release.
Precision Vaccinations post other cervical cancer vaccine updates.
Globally, nearly two million new COVID-19 cases and over 12,000 related fatalities were reported in the last 28 days, a decrease of 30% and 39%, respectively, compared to the previous 28 days, reported the World Health Organization (WHO).
As of June 1, 2023, the situation is mixed at the regional level, with increases in reported cases seen in the Western Pacific Region and the African Region and decreases in related fatalities in all six WHO regions.
During this 28-day reporting period, 150 of 243 (62%) countries and territories reported at least one COVID-19 case.
The European Region had the highest proportion of countries reporting data on new hospitalizations (19 countries; 31%).
Globally, XBB.1.5 has been reported from 115 countries since the variant emerged.
Florida Health recently published an updated Mosquito-Borne Disease Surveillance report that indicates there were three new cases of dengue confirmed last week in persons that had international travel.
As of May 27, 2023, seventy-seven travel-associated dengue cases have been reported in Florida during week #21.
And there have been two cases of locally acquired dengue in 2023.
As of June 1, 2023, the U.S. CDC reported 129 dengue cases in States and 256 dengue cases in U.S. Territories this year.
Other dengue outbreaks are posted at Vax-Before-Travel.
The journal PLOS One reported every 75 seconds, a child under five dies of malaria, and children bear the highest burden of malaria in Sub-Saharan Africa (SSA).
On May 31, 2023, the pooled prevalence of malaria among children aged 6–59 months was 27.41% (95% CI: 17.94%-36.88%) in SSA.
Infection rates range from 5.04% in Senegal to 62.57% in Sierra Leone.
This study revealed that older under-five children living in large families with low incomes in rural areas are most vulnerable to malaria infection.
To notify international travelers of their potential health risks, the U.S. CDC issued a Level 2 travel advisory focused on malaria outbreaks in Costa Rica.
While there are malaria vaccines available in June 2023, the deployment has yet to reach critical mass in SSA.
YS Biopharma Co., Ltd. today announced that its novel PIKA Rabies Vaccine was granted Phase 3 clinical trial approval from the Food and Drug Administration of the Philippines.
The Phase 3 clinical trial, which is planned to commence later in 2023, will include approximately 4,500 subjects in the Philippines, Singapore, and Pakistan.
The PIKA Rabies Vaccine has the potential to become the first accelerated three-visit one-week regimen, superior to the currently available vaccine with a five-visit one-month or three-visit three-week regimen.
The US FDA granted orphan-drug designation for preventing rabies infection, including post-exposure prophylaxis (PEP) for rabies.
The PIKA Rabies Vaccine is powered by YS Biopharma's proprietary PIKA adjuvant technology to induce accelerated immunity and produce a higher immune response.
Pending the successful completion of Phase 3 trials, the Company plans to launch the sales and marketing of the Vaccine in North America, as well as in countries throughout Asia, Africa, Europe, the Middle East, and Central and South America.
Rabies is a vaccine-preventable, zoonotic, viral disease affecting the central nervous system. It has a case-fatality rate of almost 100%.
According to the World Health Organization, about 59,000 people die of rabies annually in over 150 countries.
Over 30% of rabies victims are children.
The U.S. Centers for Disease Control and Prevention updated its recommendations for rabies preexposure prophylaxis for humans in June 2022, replacing the three-dose vaccination schedule with a two-dose program, intending to protect for about least three years.
As of June 1, 2023, there are various rabies vaccines approved.
